ViiV's new first adhesion inhibitor Rukobia was approved by the EU
Novo Nordisk invests 1.3 billion US dollars to expand the production of APIs and develop new oral drugs
AstraZeneca's Forxiga (dapagliflozin) approved in China: the world's first SGLT2 inhibitor for the treatment of heart failure!
Bayer's new-generation androgen receptor inhibitor Nubeqa® (darolutamide) was approved in China!
Nerlynx (neratinib), a tyrosine kinase inhibitor, shows strong efficacy!
The first MC4R agonist Imcivree has a strong effect in treating obesity with MC4R pathway defects!
Tyvaso DPI (inhaled treprostinil) is safe and effective: comparable to Tyvaso nebulizer!
The first drug to treat acute hyperammonemia associated with propionic acidemia and methylmalonic acidemia!
EU CHMP recommends and approves Xcopri (cenobamate): adjuvant treatment of focal epilepsy in adults!
The first nuclear export inhibitor Nexpovio (selinexor) is about to be approved by the EU, and China is under review!
Pemazyre (pemigatinib), a potent FGFR kinase inhibitor, will soon be approved in the EU
Novo Nordisk Sogroya is recommended and approved by EU CHMP
Tagrisso (osimertinib) adjuvant treatment of early EGFR mutation lung cancer: significantly prolong disease-free survival!
A new generation of tyrosine kinase inhibitor repotrectinib: total remission rate of 93%!
The U.S. FDA approves Vertex for clinical testing of fully differentiated islet cell therapy derived from stem cells!
Cancer Immunol Res: How pancreatic cancer cells escape immunotherapy
Amgen Sotorasib has strong efficacy in treating KRAS G12C mutant lung cancer (NSCLC)
Post-marketing study of Pfizer Xeljanz in the treatment of rheumatoid arthritis: lower safety than TNF inhibitors!
Merck announced Phase 2a study data: support islatravir for pre-exposure prevention (PrEP)!
AstraZeneca’s BTK inhibitor Calquence has been approved by Japan to treat relapsed/refractory CLL!